Abstract:Advances in genomics and proteomics have revolutionised the drug discovery process and target validation. Identification of novel therapeutic targets for chronic skeletal diseases is an extremely challenging process based on the difficulty of obtaining high-quality human diseased versus normal tissue samples. The quality of tissue and genomic information obtained from the sample is critical to identifying disease-related genes. Using a genomics-based approach, novel genes or genes with similar homology to existing genes can be identified from cDNA libraries generated from normal versus diseased tissue. High-quality cDNA libraries are prepared from uncontaminated homogeneous cell populations harvested from tissue sections of interest. Localised gene expression analysis and confirmation are obtained through in situ hybridisation or immunohistochemical studies. Cells overexpressing the recombinant protein are subsequently designed for primary cell-based high-throughput assays that are capable of screening large compound banks for potential hits. Afterwards, secondary functional assays are used to test promising compounds. The same overexpressing cells are used in the secondary assay to test protein activity and functionality as well as screen for small-molecule agonists or antagonists. Once a hit is generated, a structure-activity relationship of the compound is optimised for better oral bioavailability and pharmacokinetics allowing the compound to progress into development. Parallel efforts from proteomics, as well as genetics/transgenics, bioinformatics and combinatorial chemistry, and improvements in high-throughput automation technologies, allow the drug discovery process to meet the demands of the medicinal market. This review discusses and illustrates how different approaches are incorporated into the discovery and validation of novel targets and, consequently, the development of potentially therapeutic agents in the areas of osteoporosis and osteoarthritis. While current treatments exist in the form of hormone replacement therapy, antiresorptive and anabolic agents for osteoporosis, there are no disease-modifying therapies for the treatment of the most common human joint disease, osteoarthritis. A massive market potential for improved options with better safety and efficacy still remains. Therefore, the application of genomics and proteomics for both diseases should provide much needed novel therapeutic approaches to treating these major world health problems.

Surveying the landscape of emerging osteoanabolic therapies

Research and Application of Target Therapy for Osteoporosis

Recent Developments in Bone Anabolic Therapy for Osteoporosis

The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We've Come, How Much Further We Need to Go

Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases

Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials.

Genetic Approaches To Identifying Novel Osteoporosis Drug Targets

Molecular Mechanisms and Emerging Therapeutics for Osteoporosis

Recent Progresses in the Treatment of Osteoporosis

Combined physical and pharmaceutical anabolic osteoporosis therapies synergistically increase bone response and local mechanoregulation

Advances in mechanobiological pharmacokinetic-pharmacodynamic models of osteoporosis treatment - Pathways to optimise and exploit existing therapies

Latest on Anabolic Agents for Osteoporosis Treatment

Emerging Roles of Natural Compounds in Osteoporosis: Regulation, Molecular Mechanisms and Bone Regeneration

Simulating pharmaceutical treatment effects on osteoporosis via a bone remodeling algorithm targeting hypermineralized sites

The use of anabolic agents in the treatment of osteoporosis: a clinical update

Osteostatin, a peptide for the future treatment of musculoskeletal diseases

Anabolic Strategies to Augment Bone Fracture Healing

Advances in Bone Turnover Markers (PINP and CTX) in Optimizing Anti-resorptive and Anabolic Therapies Against Osteoporosis

Shoring Up Osteoporosis Management: A Fresh Start?

Physician-dentist dual referral model concept for coordinated bone anabolic therapy

Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review